latest news releases from the newsroom
Troubles Continue for Washington Mutual Inc. Employee Retirement Accounts Announces Scott+Scott LLP
NEW YORK, April 15, 2008 (PRIME NEWSWIRE) -- Beleaguered investors of Washington Mutual Inc. (NYSE:WM) were delivered more bad news by the company in Tuesday's after-hours earnings announcement. The company reported a first-quarter loss of $1.14 billion and indicated that it expects to charge off $12 billion to $19 billion of its $187 billion portfolio of single-family residential home loans in 3 to 4 years.
WSB Financial Group
Photo Release -- WSB Financial Names Terry A. Peterson President and CEO
BREMERTON, Wash., April 15, 2008 (PRIME NEWSWIRE) -- WSB Financial Group (Nasdaq:WSFG), the parent company of Westsound Bank, today announced that Terry A. Peterson has been named President and CEO effective April 15, 2008. In addition, Mr. Peterson also has been named President and CEO of Westsound Bank and will join the boards of both Westsound Bank and WSB Financial Group, Inc.
Zoltek Companies, Inc.
Zoltek Provides Guidance Regarding Second Quarter Results
ST. LOUIS, April 15, 2008 (PRIME NEWSWIRE) -- Zoltek Companies, Inc. (Nasdaq:ZOLT) today announced that it expects to report revenues of approximately $50 million in the quarter ended March 31, 2008, reflecting growth from $40.1 million reported in the quarter ended December 31, 2007 and from $36.7 million in the quarter ended March 31, 2007.
Infinity Pharmaceuticals, Inc.
Infinity's Hedgehog Antagonist Delays Tumor Growth Following Chemotherapy in Preclinical Model of Small Cell Lung Cancer; Data Presented At AACR
CAMBRIDGE, Mass., April 15, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical data from a model of small cell lung cancer (SCLC) show that following treatment with chemotherapy, once-daily oral administration of IPI-926 leads to a statistically significant delay in tumor re-growth, compared to vehicle control (p=0.01). These results suggest that inhibiting the Hedgehog pathway with IPI-926, Infinity's novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in SCLC. These data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California.